Regencell Bioscience (NASDAQ:RGC) Stock Price Down 5.1% – Should You Sell?

Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC) dropped 5.1% on Wednesday . The company traded as low as $16.18 and last traded at $15.8750. Approximately 17,632 shares traded hands during mid-day trading, a decline of 94% from the average daily volume of 276,591 shares. The stock had previously closed at $16.73.

Regencell Bioscience News Summary

Here are the key news stories impacting Regencell Bioscience this week:

• Negative Sentiment: A class action lawsuit has been filed against Regencell and certain officers, with plaintiffs alleging false and misleading statements, market-manipulation vulnerability, and exposure to regulatory and DOJ scrutiny. Article Title
• Negative Sentiment: Several law firms are actively urging investors to join or lead the case, highlighting potential compensation claims and a June 23 lead-plaintiff deadline, which keeps negative legal attention on the stock. Article Title
• Neutral Sentiment: Additional notices from firms including Rosen, Faruqi & Faruqi, Holzer & Holzer, Portnoy, and The Gross Law Firm mainly reiterate the lawsuit timeline and investor deadline rather than adding new company-specific developments.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Regencell Bioscience Price Performance

The stock’s fifty day moving average is $26.21 and its two-hundred day moving average is $25.79.

Regencell Bioscience (NASDAQ:RGC) last released its quarterly earnings data on Friday, May 8th. The company reported $0.00 earnings per share for the quarter.

Hedge Funds Weigh In On Regencell Bioscience

Several large investors have recently bought and sold shares of RGC. Squarepoint Ops LLC acquired a new position in Regencell Bioscience during the 2nd quarter valued at about $1,701,000. BNP Paribas Financial Markets acquired a new position in Regencell Bioscience during the 2nd quarter valued at about $768,000. XTX Topco Ltd acquired a new position in Regencell Bioscience during the 3rd quarter valued at about $598,000. Bank of America Corp DE increased its stake in Regencell Bioscience by 59,113.8% during the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after buying an additional 17,143 shares during the period. Finally, Hudson Bay Capital Management LP acquired a new position in Regencell Bioscience during the 4th quarter valued at about $275,000. Institutional investors and hedge funds own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.